Journal of Virus Eradication (May 2016)
Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine significantly reduces levels of HIV RNA and HIV DNA rebound following ART interruption in a phase I/II randomized controlled clinical trial
- Erwann P. Loret,
- Albert Darque,
- Elvenn A. Loret,
- Corinne Nicolino-Brunet,
- Sophie Morange,
- Elisabeth Castagnier,
- Josiane Casanova,
- Christine Caloustian,
- Charléric Bornet,
- Julie Coussirou,
- Jihen Bousseta,
- Bertrand Dussol,
- Isabelle Ravaux
Affiliations
- Erwann P. Loret
- ETRAV Laboratory CNRS/AMU, Marseille, France
- Albert Darque
- ETRAV Laboratory CNRS/AMU, Marseille, France; La Conception University Hospital, Dispensary, Marseille, France
- Elvenn A. Loret
- ETRAV Laboratory CNRS/AMU, Marseille, France
- Corinne Nicolino-Brunet
- ETRAV Laboratory CNRS/AMU, Marseille, France
- Sophie Morange
- Clinical Investigation Center, La Conception University Hospital, Marseille, France
- Elisabeth Castagnier
- Clinical Investigation Center, La Conception University Hospital, Marseille, France
- Josiane Casanova
- Clinical Investigation Center, La Conception University Hospital, Marseille, France
- Christine Caloustian
- Clinical Investigation Center, La Conception University Hospital, Marseille, France
- Charléric Bornet
- La Conception University Hospital, Dispensary, Marseille, France
- Julie Coussirou
- La Conception University Hospital, Dispensary, Marseille, France
- Jihen Bousseta
- La Conception University Hospital, Dispensary, Marseille, France
- Bertrand Dussol
- Clinical Investigation Center, La Conception University Hospital, Marseille, France
- Isabelle Ravaux
- ETRAV Laboratory CNRS/AMU, Marseille, France
- Journal volume & issue
-
Vol. 2
p. 39
